Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on 9/10/25 with a press release - check it for news.
AI Summary
On September 10, 2025, Innate Pharma SA filed a Form 6-K, reporting a press release dated September 10, 2025. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to its investors, likely containing important business or financial information.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily announces the release of a press release, without immediate new financial data or significant operational changes disclosed within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- September 10, 2025 (date) — Filing and Press Release Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated September 10, 2025, issued by Innate Pharma SA.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
Does Innate Pharma SA file annual reports under Form 20-F or Form 40-F?
Innate Pharma SA indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address for Innate Pharma SA?
The principal executive office address for Innate Pharma SA is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated September 10, is included with this 6-K filing.
Filing Stats: 158 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-09-10 06:06:48
Filing Documents
- a6k-iphx250910.htm (6-K) — 11KB
- exhibit991-250910.htm (EX-99.1) — 15KB
- 0001598599-25-000071.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 10, 2025 By s Jonathan Dickinson Name Jonathan Dickinson Title Chief Executive Officer